Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actemra in polymyalgia rheumatica
NCT01396317Phase 2Completed
- Sponsor
- Hospital for Special Surgery
- Start
- Apr 2011
- Primary completion
- Dec 2015
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of tocilizumab in polymyalgia rheumatica (PMR), sponsored by Hospital for Special Surgery. Primary endpoints: Proportion of Patients in Disease Remission at Six Months at 6 months and Number of Participants With Adverse Events at 15 months. Started Apr 2011; status: completed.
02
Drugs
tocilizumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT01396317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01396317.